{"transactions":[{"id":729123,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T20:38:47.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":13313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":13313,"derivative":{"exercise_price":15.23,"expiration_date":"2036-06-22","underlying":"Common Stock","underlying_shares":13313},"source":{"system":"sec-edgar","filing":"0001610876-26-000003","document":"wk-form4_1782247124.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000161087626000003/wk-form4_1782247124.xml","form_type":"4"}},{"id":729122,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T20:38:47.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":8141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. The settlement of such RSUs will be deferred until the earlier of (i) the 30th day following the reporting person's separation from service from the Issuer or (ii) certain change in control events."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 8,141 unvested RSUs."}],"balance_after":25388,"source":{"system":"sec-edgar","filing":"0001610876-26-000003","document":"wk-form4_1782247124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000161087626000003/wk-form4_1782247124.xml","form_type":"4"}},{"id":729164,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T20:30:34.000Z","date":"2026-06-21","kind":"grant","planned":false,"acquired":true,"shares":4200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":4200,"derivative":{"exercise_price":8.1,"expiration_date":"2036-06-20","underlying":"Common Stock","underlying_shares":4200},"source":{"system":"sec-edgar","filing":"0001610876-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000161087626000002/ownership.xml","form_type":"4"}},{"id":739840,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T21:24:20.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":648,"derivative":{"exercise_price":240.66,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":648},"source":{"system":"sec-edgar","filing":"0001689548-26-000063","document":"wk-form4_1781299458.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000063/wk-form4_1781299458.xml","form_type":"4"}},{"id":739839,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:24:20.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":1371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Dr. Chodakewitz was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":1371,"source":{"system":"sec-edgar","filing":"0001689548-26-000063","document":"wk-form4_1781299458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000063/wk-form4_1781299458.xml","form_type":"4"}},{"id":1100246,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T20:54:51.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":10520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025."}],"balance_after":10520,"derivative":{"exercise_price":44.04,"expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001689548-25-000077","document":"wk-form4_1751057685.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000077/wk-form4_1751057685.xml","form_type":"4"}},{"id":1104991,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T20:37:45.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":9341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on June 18, 2025 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":9341,"derivative":{"exercise_price":21.05,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":9341},"source":{"system":"sec-edgar","filing":"0001490978-25-000092","document":"wk-form4_1750451851.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000149097825000092/wk-form4_1750451851.xml","form_type":"4"}},{"id":1104990,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:37:45.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":5997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 18, 2025 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. The settlement of such RSUs will be deferred until the earlier of (i) the 30th day following the reporting person's separation from service from the Issuer or (ii) certain change in control events."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,997 unvested RSUs."}],"balance_after":17247,"source":{"system":"sec-edgar","filing":"0001490978-25-000092","document":"wk-form4_1750451851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000149097825000092/wk-form4_1750451851.xml","form_type":"4"}},{"id":1111748,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:08:41.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":26400,"derivative":{"exercise_price":0.78,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0000950170-25-086163","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025086163/ownership.xml","form_type":"4"}},{"id":1111747,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:08:41.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was issued Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":17700,"source":{"system":"sec-edgar","filing":"0000950170-25-086163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017025086163/ownership.xml","form_type":"4"}},{"id":1424297,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:06:57.000Z","date":"2024-08-21","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":26400,"derivative":{"exercise_price":5.195,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0000950170-24-100176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024100176/ownership.xml","form_type":"4"}},{"id":1424296,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:06:57.000Z","date":"2024-08-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0000950170-24-100176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024100176/ownership.xml","form_type":"4"}},{"id":1424295,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:06:57.000Z","date":"2024-08-21","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":11.49,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-24-100176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024100176/ownership.xml","form_type":"4"}},{"id":1424294,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:06:57.000Z","date":"2024-08-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-24-100176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024100176/ownership.xml","form_type":"4"}},{"id":1424293,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:06:57.000Z","date":"2024-08-21","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-24-100176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024100176/ownership.xml","form_type":"4"}},{"id":1424292,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:06:57.000Z","date":"2024-08-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-24-100176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024100176/ownership.xml","form_type":"4"}},{"id":1424291,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:06:57.000Z","date":"2024-08-21","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":30000,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-100176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024100176/ownership.xml","form_type":"4"}},{"id":1424290,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:06:57.000Z","date":"2024-08-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2030-09-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-100176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024100176/ownership.xml","form_type":"4"}},{"id":1473144,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-20T20:22:08.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":8550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on June 18, 2024. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":8550,"derivative":{"exercise_price":19.32,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":8550},"source":{"system":"sec-edgar","filing":"0001490978-24-000062","document":"wk-form4_1718914921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000149097824000062/wk-form4_1718914921.xml","form_type":"4"}},{"id":1473143,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T20:22:08.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2022 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 18, 2024 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,000 unvested RSUs."}],"balance_after":11250,"source":{"system":"sec-edgar","filing":"0001490978-24-000062","document":"wk-form4_1718914921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000149097824000062/wk-form4_1718914921.xml","form_type":"4"}},{"id":1486851,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:07:12.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":26400,"derivative":{"exercise_price":1.44,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0000950170-24-070613","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024070613/ownership.xml","form_type":"4"}},{"id":1486850,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:07:12.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was issued Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":11800,"source":{"system":"sec-edgar","filing":"0000950170-24-070613","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024070613/ownership.xml","form_type":"4"}},{"id":1488458,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T22:56:02.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":8566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 5, 2024."}],"balance_after":8566,"derivative":{"exercise_price":44.25,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":8566},"source":{"system":"sec-edgar","filing":"0001689548-24-000077","document":"wk-form4_1717714554.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000077/wk-form4_1717714554.xml","form_type":"4"}},{"id":1805840,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:04:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":26400,"derivative":{"exercise_price":2.14,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-23-046091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046091/doc4.xml","form_type":"4"}},{"id":1805839,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:04:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.195,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-23-046091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046091/doc4.xml","form_type":"4"}},{"id":1805838,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:04:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":2.14,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046091/doc4.xml","form_type":"4"}},{"id":1805837,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:04:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":11.49,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046091/doc4.xml","form_type":"4"}},{"id":1805836,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:04:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":2.14,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046091/doc4.xml","form_type":"4"}},{"id":1805835,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:04:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046091/doc4.xml","form_type":"4"}},{"id":1805834,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:04:28.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on September 17, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":30000,"derivative":{"exercise_price":2.14,"expiration_date":"2030-09-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-046091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046091/doc4.xml","form_type":"4"}},{"id":1805833,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:04:28.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on September 17, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-046091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123046091/doc4.xml","form_type":"4"}},{"id":1852169,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:00:40.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on June 15, 2023. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":12500,"derivative":{"exercise_price":45.26,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001490978-23-000080","document":"wk-form4_1686949225.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000149097823000080/wk-form4_1686949225.xml","form_type":"4"}},{"id":1852168,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:00:40.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2022 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 15, 2023 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Includes 6,250 unvested RSUs."}],"balance_after":6250,"source":{"system":"sec-edgar","filing":"0001490978-23-000080","document":"wk-form4_1686949225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000149097823000080/wk-form4_1686949225.xml","form_type":"4"}},{"id":1855940,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T11:13:49.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":28981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 12, 2023."}],"balance_after":28981,"derivative":{"exercise_price":0.957,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":28981},"source":{"system":"sec-edgar","filing":"0001689548-23-000110","document":"wf-form4_168674121504095.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954823000110/wf-form4_168674121504095.xml","form_type":"4"}},{"id":1870050,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T21:50:00.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":26400,"derivative":{"exercise_price":5.195,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-23-033961","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123033961/doc4.xml","form_type":"4"}},{"id":1870049,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T21:50:00.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was issued Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":5900,"source":{"system":"sec-edgar","filing":"0001209191-23-033961","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919123033961/doc4.xml","form_type":"4"}},{"id":2229924,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T21:00:43.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":14907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 15, 2022. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":14907,"derivative":{"exercise_price":24.51,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":14907},"source":{"system":"sec-edgar","filing":"0001209191-22-037481","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000120919122037481/doc4.xml","form_type":"4"}},{"id":2244881,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:37:44.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":18500,"derivative":{"exercise_price":11.49,"expiration_date":"2032-06-01","underlying":"Common stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-22-034082","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919122034082/doc4.xml","form_type":"4"}},{"id":2253545,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T21:27:24.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":22753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on May 26, 2022."}],"balance_after":22753,"derivative":{"exercise_price":8.38,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":22753},"source":{"system":"sec-edgar","filing":"0001689548-22-000068","document":"wf-form4_165368682652738.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954822000068/wf-form4_165368682652738.xml","form_type":"4"}},{"id":2660981,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T21:00:35.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":8736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 17, 2021. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service."}],"balance_after":8736,"derivative":{"exercise_price":76.08,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":8736},"source":{"system":"sec-edgar","filing":"0001209191-21-042096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000120919121042096/doc4.xml","form_type":"4"}},{"id":2730294,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-04T23:21:36.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":18500,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-21-030095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000120919121030095/doc4.xml","form_type":"4"}},{"id":2748665,"issuer":{"id":3538,"kind":"organization","name":"Praxis Precision Medicines, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-15T20:24:00.000Z","date":"2021-04-13","kind":"grant","acquired":true,"shares":38579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on April 13, 2021."}],"balance_after":38579,"derivative":{"exercise_price":30.37,"expiration_date":"2031-04-13","underlying":"Common Stock","underlying_shares":38579},"source":{"system":"sec-edgar","filing":"0001689548-21-000020","document":"wf-form4_161851822364094.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954821000020/wf-form4_161851822364094.xml","form_type":"4"}},{"id":3028650,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-18T01:50:34.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest as follows:  1/36th of the shares shall vest on each of the next thirty-six (36) monthly anniversaries of the Vesting Commencement Date."}],"balance_after":30000,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-025645","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924320025645/doc4.xml","form_type":"4"}},{"id":3120582,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-05T20:30:52.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":14414,"derivative":{"exercise_price":2.23,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0000899243-20-015447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924320015447/doc4.xml","form_type":"4"}},{"id":3163663,"issuer":{"id":4667,"kind":"organization","name":"Schrodinger, Inc.","symbol":"SDGR"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-04T11:21:07.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":25216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 30, 2020. The shares underlying the option are scheduled to vest in equal yearly installments through April 30, 2023, subject to continued service."}],"balance_after":25216,"derivative":{"exercise_price":46.4,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":25216},"source":{"system":"sec-edgar","filing":"0000899243-20-011840","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000089924320011840/doc4.xml","form_type":"4"}},{"id":3494260,"issuer":{"id":147285,"kind":"organization","name":"TETRAPHASE PHARMACEUTICALS INC","symbol":"TTPH"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-06-11T23:17:46.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in equal quarterly installments over a one-year period measured from the date of grant."}],"balance_after":16500,"derivative":{"exercise_price":0.77,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-19-036255","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000120919119036255/doc4.xml","form_type":"4"}},{"id":3533695,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-09T22:44:51.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":14414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 8, 2019 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":14414,"derivative":{"exercise_price":7.99,"expiration_date":"2029-05-07","underlying":"Common Stock","underlying_shares":14414},"source":{"system":"sec-edgar","filing":"0000899243-19-012921","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924319012921/doc4.xml","form_type":"4"}},{"id":3843483,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-15T12:25:22.000Z","date":"2018-08-14","kind":"grant","acquired":true,"shares":28828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares shall vest on August 14, 2019, with the remainder vesting ratably monthly thereafter."}],"balance_after":28828,"derivative":{"exercise_price":10.42,"expiration_date":"2028-08-14","underlying":"Common Stock","underlying_shares":28828},"source":{"system":"sec-edgar","filing":"0000899243-18-022429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924318022429/doc4.xml","form_type":"4"}},{"id":3910800,"issuer":{"id":147285,"kind":"organization","name":"TETRAPHASE PHARMACEUTICALS INC","symbol":"TTPH"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-06-01T20:13:36.000Z","date":"2018-05-30","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in equal quarterly installments over a one-year period measured from the date of grant."}],"balance_after":12500,"derivative":{"exercise_price":3.68,"expiration_date":"2028-05-29","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-18-034653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610876/000120919118034653/doc4.xml","form_type":"4"}},{"id":419173,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-14T23:15:43.000Z","date":"2018-02-12","kind":"sale","acquired":false,"shares":300,"price":153.69,"value":46107.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $153.69 (range $153.59 to $153.90)."}],"balance_after":69663,"source":{"system":"sec-edgar","filing":"0001209191-18-010119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118010119/doc4.xml","form_type":"4"}},{"id":419172,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-14T23:15:43.000Z","date":"2018-02-12","kind":"sale","acquired":false,"shares":400,"price":152.62,"value":61048.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $152.62 (range $152.09 to $152.96)."}],"balance_after":69963,"source":{"system":"sec-edgar","filing":"0001209191-18-010119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118010119/doc4.xml","form_type":"4"}},{"id":419171,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-14T23:15:43.000Z","date":"2018-02-12","kind":"sale","acquired":false,"shares":2022,"price":151.26,"value":305847.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $151.26 (range $150.88 to $151.86)."}],"balance_after":70363,"source":{"system":"sec-edgar","filing":"0001209191-18-010119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118010119/doc4.xml","form_type":"4"}},{"id":419170,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-14T23:15:43.000Z","date":"2018-02-12","kind":"sale","acquired":false,"shares":1100,"price":150.47,"value":165517.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $150.47 (range $149.83 to $150.76)."}],"balance_after":72385,"source":{"system":"sec-edgar","filing":"0001209191-18-010119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118010119/doc4.xml","form_type":"4"}},{"id":419169,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-14T23:15:43.000Z","date":"2018-02-12","kind":"sale","acquired":false,"shares":1300,"price":149.21,"value":193973.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $149.21 (range $148.80 to $149.64)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":73485,"source":{"system":"sec-edgar","filing":"0001209191-18-010119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118010119/doc4.xml","form_type":"4"}},{"id":419456,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-08T22:49:22.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":23479,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in 16 quarterly installments from 2/6/2018."}],"balance_after":23479,"derivative":{"exercise_price":155.57,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":23479},"source":{"system":"sec-edgar","filing":"0001209191-18-008515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008515/doc4.xml","form_type":"4"}},{"id":419455,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-08T22:49:22.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":10125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Restricted stock unit award that vests in three equal installments on 2/17/2019, 2/17/2020 and 2/17/2021."}],"balance_after":74785,"source":{"system":"sec-edgar","filing":"0001209191-18-008515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008515/doc4.xml","form_type":"4"}},{"id":419454,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-08T22:49:22.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":12136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2017 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 2/6/2018. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020."}],"balance_after":64660,"source":{"system":"sec-edgar","filing":"0001209191-18-008515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008515/doc4.xml","form_type":"4"}},{"id":419485,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-07T23:16:30.000Z","date":"2018-02-05","kind":"exercise","acquired":false,"shares":3594,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vests in 16 quarterly installments from 2/3/2015."}],"balance_after":14375,"derivative":{"exercise_price":109.14,"expiration_date":"2025-02-02","underlying":"Common Stock","underlying_shares":3594},"source":{"system":"sec-edgar","filing":"0001209191-18-008224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008224/doc4.xml","form_type":"4"}},{"id":419484,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-07T23:16:30.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":100,"price":164.71,"value":16471.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."}],"balance_after":52524,"source":{"system":"sec-edgar","filing":"0001209191-18-008224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008224/doc4.xml","form_type":"4"}},{"id":419483,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-07T23:16:30.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":900,"price":164.12,"value":147708.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $164.12 (range $163.65 to $164.53)."}],"balance_after":52624,"source":{"system":"sec-edgar","filing":"0001209191-18-008224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008224/doc4.xml","form_type":"4"}},{"id":419482,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-07T23:16:30.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":400,"price":162.94,"value":65176.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $162.94 (range $162.52 to $163.40)."}],"balance_after":53524,"source":{"system":"sec-edgar","filing":"0001209191-18-008224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008224/doc4.xml","form_type":"4"}},{"id":419481,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-07T23:16:30.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":500,"price":161.51,"value":80755.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $161.51 (range $161.32 to $161.85)."}],"balance_after":53924,"source":{"system":"sec-edgar","filing":"0001209191-18-008224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008224/doc4.xml","form_type":"4"}},{"id":419480,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-07T23:16:30.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":500,"price":160.5,"value":80250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of  $160.50 (range $160.20 to $160.86)."}],"balance_after":54424,"source":{"system":"sec-edgar","filing":"0001209191-18-008224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008224/doc4.xml","form_type":"4"}},{"id":419479,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-07T23:16:30.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":700,"price":159.62,"value":111734.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $159.62 (range $159.18 to $160.06)."}],"balance_after":54924,"source":{"system":"sec-edgar","filing":"0001209191-18-008224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008224/doc4.xml","form_type":"4"}},{"id":419478,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-07T23:16:30.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":494,"price":158.32,"value":78210.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $158.32 (range $158.01 to $158.82)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":55624,"source":{"system":"sec-edgar","filing":"0001209191-18-008224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008224/doc4.xml","form_type":"4"}},{"id":419477,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-07T23:16:30.000Z","date":"2018-02-05","kind":"exercise","acquired":true,"shares":3594,"price":109.14,"value":392249.16,"ownership":{"direct":true},"balance_after":56118,"source":{"system":"sec-edgar","filing":"0001209191-18-008224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118008224/doc4.xml","form_type":"4"}},{"id":419608,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-05T22:43:00.000Z","date":"2018-02-02","kind":"exercise","acquired":false,"shares":1796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in 16 quarterly installments from 2/2/2016."}],"balance_after":14368,"derivative":{"exercise_price":91.05,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":1796},"source":{"system":"sec-edgar","filing":"0001209191-18-007617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118007617/doc4.xml","form_type":"4"}},{"id":419607,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-05T22:43:00.000Z","date":"2018-02-02","kind":"sale","acquired":false,"shares":100,"price":169.49,"value":16949.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."}],"balance_after":52524,"source":{"system":"sec-edgar","filing":"0001209191-18-007617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118007617/doc4.xml","form_type":"4"}},{"id":419606,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-05T22:43:00.000Z","date":"2018-02-02","kind":"sale","acquired":false,"shares":100,"price":168.06,"value":16806.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."}],"balance_after":52624,"source":{"system":"sec-edgar","filing":"0001209191-18-007617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118007617/doc4.xml","form_type":"4"}},{"id":419605,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-05T22:43:00.000Z","date":"2018-02-02","kind":"sale","acquired":false,"shares":996,"price":166.1,"value":165435.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $166.10 (range $165.81 to $166.43)."}],"balance_after":52724,"source":{"system":"sec-edgar","filing":"0001209191-18-007617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118007617/doc4.xml","form_type":"4"}},{"id":419604,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-05T22:43:00.000Z","date":"2018-02-02","kind":"sale","acquired":false,"shares":600,"price":165.23,"value":99138.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $165.23 (range $164.80 to $165.67)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":53720,"source":{"system":"sec-edgar","filing":"0001209191-18-007617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118007617/doc4.xml","form_type":"4"}},{"id":419603,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-05T22:43:00.000Z","date":"2018-02-02","kind":"exercise","acquired":true,"shares":1796,"price":91.05,"value":163525.8,"ownership":{"direct":true},"balance_after":54320,"source":{"system":"sec-edgar","filing":"0001209191-18-007617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118007617/doc4.xml","form_type":"4"}},{"id":419602,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-02-05T22:43:00.000Z","date":"2018-02-01","kind":"sale","acquired":false,"shares":1900,"price":167.44,"value":318136.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."}],"balance_after":52524,"source":{"system":"sec-edgar","filing":"0001209191-18-007617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118007617/doc4.xml","form_type":"4"}},{"id":420465,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-17T21:38:27.000Z","date":"2018-01-16","kind":"exercise","acquired":false,"shares":1719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in 16 quarterly installments from 7/15/2014."}],"balance_after":3438,"derivative":{"exercise_price":96.87,"expiration_date":"2024-07-14","underlying":"Common Stock","underlying_shares":1719},"source":{"system":"sec-edgar","filing":"0001209191-18-003958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118003958/doc4.xml","form_type":"4"}},{"id":420464,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-01-17T21:38:27.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":300,"price":159.04,"value":47712.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."}],"balance_after":54424,"source":{"system":"sec-edgar","filing":"0001209191-18-003958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118003958/doc4.xml","form_type":"4"}},{"id":420463,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-01-17T21:38:27.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":900,"price":157.54,"value":141786.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $157.54 (range $156.95 to $157.83)."}],"balance_after":54724,"source":{"system":"sec-edgar","filing":"0001209191-18-003958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118003958/doc4.xml","form_type":"4"}},{"id":420462,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-01-17T21:38:27.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":519,"price":155.8,"value":80860.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $155.80 (range $155.77 to $155.91)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":55624,"source":{"system":"sec-edgar","filing":"0001209191-18-003958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118003958/doc4.xml","form_type":"4"}},{"id":420461,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-01-17T21:38:27.000Z","date":"2018-01-16","kind":"exercise","acquired":true,"shares":1719,"price":96.87,"value":166519.53,"ownership":{"direct":true},"balance_after":56143,"source":{"system":"sec-edgar","filing":"0001209191-18-003958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118003958/doc4.xml","form_type":"4"}},{"id":420747,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-03T21:56:55.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":3438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":73.51,"expiration_date":"2024-01-01","underlying":"Common Stock","underlying_shares":3438},"source":{"system":"sec-edgar","filing":"0001209191-18-001000","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118001000/doc4.xml","form_type":"4"}},{"id":420746,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-01-03T21:56:55.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":863,"price":152.8,"value":131866.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $152.80 (range $152.70 to $153.03)."}],"balance_after":54424,"source":{"system":"sec-edgar","filing":"0001209191-18-001000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118001000/doc4.xml","form_type":"4"}},{"id":420745,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-01-03T21:56:55.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":1600,"price":152.06,"value":243296.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $152.06 (range $151.70 to $152.69)."}],"balance_after":55287,"source":{"system":"sec-edgar","filing":"0001209191-18-001000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118001000/doc4.xml","form_type":"4"}},{"id":420744,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-01-03T21:56:55.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":675,"price":150.87,"value":101837.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $150.87 (range $150.53 to $151.50)."}],"balance_after":56887,"source":{"system":"sec-edgar","filing":"0001209191-18-001000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118001000/doc4.xml","form_type":"4"}},{"id":420743,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-01-03T21:56:55.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":300,"price":149.65,"value":44895.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $149.65 (range $149.41 to $149.92)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":57562,"source":{"system":"sec-edgar","filing":"0001209191-18-001000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118001000/doc4.xml","form_type":"4"}},{"id":420742,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2018-01-03T21:56:55.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":3438,"price":73.51,"value":252727.38,"ownership":{"direct":true},"balance_after":57862,"source":{"system":"sec-edgar","filing":"0001209191-18-001000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919118001000/doc4.xml","form_type":"4"}},{"id":422442,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-06T22:50:02.000Z","date":"2017-11-03","kind":"exercise","acquired":false,"shares":3594,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests in 16 quarterly installments from 2/3/2015."}],"balance_after":17969,"derivative":{"exercise_price":109.14,"expiration_date":"2025-02-02","underlying":"Common Stock","underlying_shares":3594},"source":{"system":"sec-edgar","filing":"0001209191-17-059474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117059474/doc4.xml","form_type":"4"}},{"id":422441,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-06T22:50:02.000Z","date":"2017-11-02","kind":"exercise","acquired":false,"shares":1796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in 16 quarterly installments from 2/2/2016."}],"balance_after":16164,"derivative":{"exercise_price":91.05,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":1796},"source":{"system":"sec-edgar","filing":"0001209191-17-059474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117059474/doc4.xml","form_type":"4"}},{"id":422440,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-11-06T22:50:02.000Z","date":"2017-11-03","kind":"sale","acquired":false,"shares":3594,"price":144.69,"value":520015.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $144.69 (range $144.19 to $144.90)."}],"balance_after":54424,"source":{"system":"sec-edgar","filing":"0001209191-17-059474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117059474/doc4.xml","form_type":"4"}},{"id":422439,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-11-06T22:50:02.000Z","date":"2017-11-03","kind":"exercise","acquired":true,"shares":3594,"price":109.14,"value":392249.16,"ownership":{"direct":true},"balance_after":58018,"source":{"system":"sec-edgar","filing":"0001209191-17-059474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117059474/doc4.xml","form_type":"4"}},{"id":422438,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-11-06T22:50:02.000Z","date":"2017-11-02","kind":"sale","acquired":false,"shares":300,"price":145.89,"value":43767.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $145.89 (range $145.63 to $146.04)."}],"balance_after":54424,"source":{"system":"sec-edgar","filing":"0001209191-17-059474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117059474/doc4.xml","form_type":"4"}},{"id":422437,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-11-06T22:50:02.000Z","date":"2017-11-02","kind":"sale","acquired":false,"shares":1096,"price":144.89,"value":158799.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $144.89 (range $144.48 to $145.18)."}],"balance_after":54724,"source":{"system":"sec-edgar","filing":"0001209191-17-059474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117059474/doc4.xml","form_type":"4"}},{"id":422436,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-11-06T22:50:02.000Z","date":"2017-11-02","kind":"sale","acquired":false,"shares":400,"price":143.54,"value":57416.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $143.54 (range $142.98 to $143.81)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":55820,"source":{"system":"sec-edgar","filing":"0001209191-17-059474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117059474/doc4.xml","form_type":"4"}},{"id":422435,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-11-06T22:50:02.000Z","date":"2017-11-02","kind":"exercise","acquired":true,"shares":1796,"price":91.05,"value":163525.8,"ownership":{"direct":true},"balance_after":56220,"source":{"system":"sec-edgar","filing":"0001209191-17-059474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117059474/doc4.xml","form_type":"4"}},{"id":422662,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-10-31T22:15:02.000Z","date":"2017-10-31","kind":"sale","acquired":false,"shares":200,"price":149.34,"value":29868.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."}],"balance_after":54424,"source":{"system":"sec-edgar","filing":"0001209191-17-058479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117058479/doc4.xml","form_type":"4"}},{"id":422661,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-10-31T22:15:02.000Z","date":"2017-10-31","kind":"sale","acquired":false,"shares":1400,"price":148.4,"value":207760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Open market sales reported on this line occurred at a weighted average price of $148.40 (range $148.19 to $148.70)."}],"balance_after":54624,"source":{"system":"sec-edgar","filing":"0001209191-17-058479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117058479/doc4.xml","form_type":"4"}},{"id":422660,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-10-31T22:15:02.000Z","date":"2017-10-31","kind":"sale","acquired":false,"shares":3400,"price":147.75,"value":502350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $147.75 (range $147.18 to $148.15)."}],"balance_after":56024,"source":{"system":"sec-edgar","filing":"0001209191-17-058479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117058479/doc4.xml","form_type":"4"}},{"id":422659,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-10-31T22:15:02.000Z","date":"2017-10-31","kind":"sale","acquired":false,"shares":4700,"price":146.52,"value":688644.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $146.52 (range $146.16 to $147.14)."}],"balance_after":59424,"source":{"system":"sec-edgar","filing":"0001209191-17-058479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117058479/doc4.xml","form_type":"4"}},{"id":422658,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-10-31T22:15:02.000Z","date":"2017-10-31","kind":"sale","acquired":false,"shares":19016,"price":145.26,"value":2762264.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.91 to $145.87)."}],"balance_after":64124,"source":{"system":"sec-edgar","filing":"0001209191-17-058479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117058479/doc4.xml","form_type":"4"}},{"id":422657,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-10-31T22:15:02.000Z","date":"2017-10-31","kind":"sale","acquired":false,"shares":25784,"price":144.46,"value":3724756.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $144.46 (range $143.90 to $144.89)."}],"balance_after":83140,"source":{"system":"sec-edgar","filing":"0001209191-17-058479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117058479/doc4.xml","form_type":"4"}},{"id":422656,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-10-31T22:15:02.000Z","date":"2017-10-31","kind":"sale","acquired":false,"shares":4100,"price":143.46,"value":588186.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $143.46 (range $142.87 to $143.85)."}],"balance_after":108924,"source":{"system":"sec-edgar","filing":"0001209191-17-058479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117058479/doc4.xml","form_type":"4"}},{"id":422655,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":16105,"kind":"person","name":"Chodakewitz Jeffrey","position":1,"cik":"0001610876","reported_name":"Chodakewitz Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP GMDA, CMO"}}],"security":"Common Stock","published_at":"2017-10-31T22:15:02.000Z","date":"2017-10-31","kind":"sale","acquired":false,"shares":1400,"price":142.38,"value":199332.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $142.38 (range $141.83 to $142.81)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":113024,"source":{"system":"sec-edgar","filing":"0001209191-17-058479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919117058479/doc4.xml","form_type":"4"}}],"next_cursor":"2017-10-31T22:15:02.000000Z,422655"}